September 18, 2015
Chugai Pharmaceutical said on September 17 that it has filed its mainstay anticancer agent Avastin (bevacizumab) for an additional indication of recurrent or advanced cervical cancer. The drug has been designated as an orphan drug for the cervical cancer indication...read more